Key result
BNP plasma concentrations were significantly higher in GRMD dogs than in controls (117 vs 46 pg/mL, P < .05), showing potential as a marker for asymptomatic cardiomyopathy in adult dogs.
Why the study?
Can plasma concentrations of ANP and BNP serve as reliable markers of cardiac alterations during occult cardiomyopathy in Golden Retriever Muscular Dystrophy?
Cross-Sectional (n=50)
Can plasma concentrations of ANP and BNP serve as reliable markers of cardiac alterations during occult cardiomyopathy in Golden Retriever Muscular Dystrophy?
Absolute Event Rate: 117% vs 46%
p-value: p=<.05
BNP, but not ANP, is a potentially useful biochemical marker for detecting asymptomatic cardiomyopathy in adult dogs with Golden Retriever Muscular Dystrophy.
May support BNP as marker in GRMD models; hypothesis-generating for clinical veterinary validation.
The objective of the study was to determine whether the plasma concentrations of atrial and brain natriuretic peptides (ANP and BNP, respectively) could be reliable markers of cardiac alterations during occult cardiomyopathy in Golden Retriever Muscular Dystrophy (GRMD). Fifty Golden Retrievers without any clinical or radiographic sign of heart disease were included in this study (21 GRMD dogs and 29 controls). Controls and GRMD dogs were divided into 2 subgroups according to age (< and > or =12 months old, respectively). All dogs underwent echocardiography and determination of BNP and ANP plasma concentrations by radioimmunoassay. No ventricular dilatation or dysfunction was observed in either control or GRMD dogs. ANP plasma concentration did not differ significantly between controls and GRMD dogs (mean +/- SD = 72 +/- 49 versus 58 +/- 23 pg/mL, respectively, P = .21). This finding was confirmed in both subgroups of dogs (ie, those < and > or =12 months old). In contrast, BNP plasma concentrations were significantly higher in GRMD dogs than in controls (mean +/- SD = 117 +/- 92 versus 46 +/- 22 pg/mL, respectively, P < .05). In dogs > or =12 months old, sensitivity and specificity of BNP for identifying GRMD with a cutoff of 65 pg/mL were 78 and 86%, respectively. For the same cutoff value, sensitivity dropped to 42%, whereas specificity reached 100% in dogs <12 months old. In conclusion, BNP may be a useful biochemical marker of asymptomatic cardiomyopathy. However, this peptide does not allow very early detection because its optimal discriminatory power was observed in adult dogs (ie, > or =12 months of age).
No takes yet. Share an insight, caveat, or question.
Chetboul et al. (2004) conducted a cross-sectional in Golden Retriever Muscular Dystrophy (GRMD) occult cardiomyopathy (n=50). Golden Retriever Muscular Dystrophy (GRMD) vs. Healthy controls was evaluated on BNP plasma concentration (pg/mL) (p=<.05). BNP plasma concentrations were significantly higher in GRMD dogs than in controls (117 vs 46 pg/mL, P < .05), showing potential as a marker for asymptomatic cardiomyopathy in adult dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: